Peakdale Molecular - News

PEAKDALE MOLECULAR ANNOUNCES GBP1 MILLION FUNDING TO SUPPORT EXPANSION AND GROWTH.

Chapel-en-le-Frith, UK, 9th January 2008

Peakdale Molecular Ltd (CHAPEL-EN-LE-FRITH, UK) a leading provider in specialist chemistry services to the pharmaceutical industry has announced today that they have successfully completed a GBP1m round of equity funding which will enable Peakdale to continue the expansion of its facilities in the UK to support its continued rapid growth.

The investors in this round were led by Solon Ventures LP, advised by Solon Ventures Ltd, and were supported by a number of existing investors.

Commenting on the deal, Peakdale's Commercial Director Ray Fisher said: "I am very grateful for being introduced to the team at Solon Ventures at such an important time in Peakdale's history. With our plans for aggressive growth, Solon's sector knowledge and desire to actively support such activities, together we appear to have the ingredients of a perfect synergy."

Adding to this, Solon Ventures Ltd Managing Director Angus Whiteley said: "We are delighted to be involved with Ray and his team at Peakdale in this exciting stage of its development. With its excellent reputation and high quality services, we believe Peakdale is very well placed to continue to support the pharmaceutical and biotech industries in the future. We look forward to playing an active role, based on our experience of the sector, in helping the company achieve its growth and international aspirations."

Solon Ventures LP is a Jersey-based limited partnership that invests in private UK healthcare and technology companies. The fund is advised by Solon Ventures Ltd, a UK company that advises GBP35m of venture capital investment for a range of clients. www.solonventures.com

FOR MORE INFORMATION REGARDING THIS NEWS
ARTICLE PLEASE CONTACT

Sarah Barratt
Marketing Executive
Peakdale Molecular Ltd
01298 816 700
sarah.barratt@peakdale.co.uk